These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 37039914)

  • 1. Mechanisms of preferential bone formation in myeloma bone lesions by proteasome inhibitors.
    Nakaue E; Teramachi J; Tenshin H; Hiasa M; Harada T; Oda A; Inoue Y; Shimizu S; Higa Y; Sogabe K; Oura M; Hara T; Sumitani R; Maruhashi T; Yamagami H; Endo I; Tanaka E; Abe M
    Int J Hematol; 2023 Jul; 118(1):88-98. PubMed ID: 37039914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.
    Hurchla MA; Garcia-Gomez A; Hornick MC; Ocio EM; Li A; Blanco JF; Collins L; Kirk CJ; Piwnica-Worms D; Vij R; Tomasson MH; Pandiella A; San Miguel JF; Garayoa M; Weilbaecher KN
    Leukemia; 2013 Feb; 27(2):430-40. PubMed ID: 22763387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling.
    Accardi F; Toscani D; Bolzoni M; Dalla Palma B; Aversa F; Giuliani N
    Biomed Res Int; 2015; 2015():172458. PubMed ID: 26579531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease.
    Garcia-Gomez A; Quwaider D; Canavese M; Ocio EM; Tian Z; Blanco JF; Berger AJ; Ortiz-de-Solorzano C; Hernández-Iglesias T; Martens AC; Groen RW; Mateo-Urdiales J; Fraile S; Galarraga M; Chauhan D; San Miguel JF; Raje N; Garayoa M
    Clin Cancer Res; 2014 Mar; 20(6):1542-54. PubMed ID: 24486586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
    Kupisiewicz K
    Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute accumulation of PIM2 and NRF2 and recovery of β5 subunit activity mitigate multiple myeloma cell susceptibility to proteasome inhibitors.
    Sogabe K; Nakamura S; Higa Y; Miki H; Oda A; Maruhashi T; Sumitani R; Oura M; Takahashi M; Nakamura M; Maeda Y; Hara T; Yamagami H; Fujii S; Kagawa K; Ozaki S; Kurahashi K; Endo I; Aihara KI; Nakaue E; Hiasa M; Teramachi J; Harada T; Abe M
    Int J Hematol; 2024 Mar; 119(3):303-315. PubMed ID: 38245883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteasome inhibitors and bone disease.
    Qiang YW; Heuck CJ; Shaughnessy JD; Barlogie B; Epstein J
    Semin Hematol; 2012 Jul; 49(3):243-8. PubMed ID: 22726547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of proteasome inhibitors for treatment of multiple myeloma.
    Schlafer D; Shah KS; Panjic EH; Lonial S
    Expert Opin Drug Saf; 2017 Feb; 16(2):167-183. PubMed ID: 27841029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of proteasome inhibitors on bone remodeling in multiple myeloma.
    Zangari M; Suva LJ
    Bone; 2016 May; 86():131-8. PubMed ID: 26947893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors.
    Toscani D; Palumbo C; Dalla Palma B; Ferretti M; Bolzoni M; Marchica V; Sena P; Martella E; Mancini C; Ferri V; Costa F; Accardi F; Craviotto L; Aversa F; Giuliani N
    J Bone Miner Res; 2016 Apr; 31(4):815-27. PubMed ID: 26551485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteoblastogenesis and tumor growth in myeloma.
    Yaccoby S
    Leuk Lymphoma; 2010 Feb; 51(2):213-20. PubMed ID: 20038269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Role of novel proteasome inhibitors in the treatment of relapsed/refractory multiple myeloma].
    Ri M
    Rinsho Ketsueki; 2018; 59(10):2162-2168. PubMed ID: 30305522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural Agents as Novel Potential Source of Proteasome Inhibitors with Anti-Tumor Activity: Focus on Multiple Myeloma.
    Ambrosio FA; Costa G; Gallo Cantafio ME; Torcasio R; Trapasso F; Alcaro S; Viglietto G; Amodio N
    Molecules; 2023 Feb; 28(3):. PubMed ID: 36771100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased Bone Volume by Ixazomib in Multiple Myeloma: 3-Month Results from an Open Label Phase 2 Study.
    Diaz-delCastillo M; Gundesen MT; Andersen CW; Nielsen AL; Møller HEH; Vinholt PJ; Asmussen JT; Kristensen IB; Nyvold CG; Abildgaard N; Levin Andersen T; Lund T
    J Bone Miner Res; 2023 May; 38(5):639-649. PubMed ID: 36970780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Research progress in proteasome inhibitor resistance to multiple myeloma.
    Wu J; Liu J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 46(8):900-908. PubMed ID: 34565737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxidatively modified low-density lipoproteins are potential mediators of proteasome inhibitor resistance in multiple myeloma.
    Polusani SR; Cortez V; Esparza J; Nguyen HN; Fan H; Velagaleti GVN; Butler MJ; Kinney MC; Oyajobi BO; Habib SL; Asmis R; Medina EA
    Int J Cancer; 2021 Jun; 148(12):3032-3040. PubMed ID: 33521927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Proteasome and Myeloma-Associated Bone Disease.
    Accardi F; Toscani D; Costa F; Aversa F; Giuliani N
    Calcif Tissue Int; 2018 Feb; 102(2):210-226. PubMed ID: 29080972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors.
    Besse A; Besse L; Kraus M; Mendez-Lopez M; Bader J; Xin BT; de Bruin G; Maurits E; Overkleeft HS; Driessen C
    Cell Chem Biol; 2019 Mar; 26(3):340-351.e3. PubMed ID: 30612952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Old and new generation proteasome inhibitors in multiple myeloma.
    Montefusco V; Mussetti A; Salas MQ; Martinelli G; Cerchione C
    Panminerva Med; 2020 Dec; 62(4):193-206. PubMed ID: 32957744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling.
    Kaiser MF; Heider U; Mieth M; Zang C; von Metzler I; Sezer O
    Eur J Haematol; 2013 Apr; 90(4):263-72. PubMed ID: 23311753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.